Amgen's net income for the quarter fell 17% from a year earlier to $1.8 billion, driven primarily by costs associated with the Otezla deal and accounting for losses at Chinese partner BeiGene Ltd.Amgen also expects key clinical data in the second half of this year from trials of experimental drugs, including tezepelumab in patients with severe asthma and heart failure treatment omecamtiv mecarbil.